Cargando…

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma—namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors (ICIs), and targeted immunotherapies—may offer an improved survival benefit by overcoming limitations associated with any individual therapy. Still, optimal combinat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stopfer, Lauren E., Rettko, Nicholas J., Leddy, Owen, Mesfin, Joshua M., Brown, Eric, Winski, Shannon, Bryson, Bryan, Wells, James A., White, Forest M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2022
Materias:	Biological Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894220/ https://www.ncbi.nlm.nih.gov/pubmed/36454758 http://dx.doi.org/10.1073/pnas.2208900119

Ejemplares similares

Immunopeptidomics reveals determinants of Mycobacterium tuberculosis antigen presentation on MHC class I
por: Leddy, Owen, et al.
Publicado: (2023)

Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition
por: Stopfer, Lauren E., et al.
Publicado: (2020)

Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrants
por: Stopfer, Lauren E., et al.
Publicado: (2021)

Leveraging Immunopeptidomics To Study and Combat Infectious Disease
por: Leddy, Owen K., et al.
Publicado: (2021)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

MIG6 is MEK-regulated and affects EGF-induced migration in mutant NRAS melanoma
por: Vu, Ha Linh, et al.
Publicado: (2015)

HSP70 Inhibition Blocks Adaptive Resistance and Synergizes with MEK Inhibition for the Treatment of NRAS-Mutant Melanoma
por: Parris, Joshua L.D., et al.
Publicado: (2021)

Quantitative Consequences of Protein Carriers in Immunopeptidomics and Tyrosine Phosphorylation MS(2) Analyses
por: Stopfer, Lauren E., et al.
Publicado: (2021)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

1,2,3, MHC: a review of mass-spectrometry-based immunopeptidomics methods for relative and absolute quantification of pMHCs
por: Stopfer, L.E., et al.
Publicado: (2021)

MHC and antigen in exosomes
por: LeBrasseur, Nicole
Publicado: (2007)

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status
por: Byron, Sara A, et al.
Publicado: (2012)

Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma
por: Posch, C, et al.
Publicado: (2015)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Signaling for death: tyrosine phosphorylation in the response to glucose deprivation
por: Bryson, Bryan D, et al.
Publicado: (2012)

Quantitative Profiling of Lysine Acetylation Reveals Dynamic Crosstalk between Receptor Tyrosine Kinases and Lysine Acetylation
por: Bryson, Bryan D., et al.
Publicado: (2015)

Intermittent MEK inhibition for the treatment of metastatic uveal melanoma
por: Khan, Shaheer, et al.
Publicado: (2022)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma
por: Forschner, Andrea, et al.
Publicado: (2021)

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
por: Spagnolo, Francesco, et al.
Publicado: (2021)

Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma
por: Zhao, Qian, et al.
Publicado: (2022)

Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
por: Maeda, Takuya, et al.
Publicado: (2023)

BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma
por: Mehnert, Janice M., et al.
Publicado: (2022)

Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins
por: Fessenden, Tim B, et al.
Publicado: (2022)

Antigen Processing by Macroautophagy for MHC Presentation
por: Münz, Christian
Publicado: (2011)

Antigen processing for MHC presentation by autophagy
por: Münz, Christian
Publicado: (2010)

Antigen Presentation by MHC-Dressed Cells
por: Nakayama, Masafumi
Publicado: (2015)

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
por: Sweetlove, Melanie, et al.
Publicado: (2015)

A genome‐wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS‐mutant melanoma
por: Nagler, Adi, et al.
Publicado: (2019)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

MEK targeting in N-RAS mutated metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2014)

Trametinib: a MEK inhibitor for management of metastatic melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Mutant HRAS as novel target for MEK and mTOR inhibitors
por: Kiessling, Michael K., et al.
Publicado: (2015)

MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression
por: Franklin, Derek A., et al.
Publicado: (2020)

MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma
por: Engelhard, Victor H, et al.
Publicado: (2020)

Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma
por: Yu, Jing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a7m0pqqr5jugpcjn0t6ef6mv2j